loading page

Ocular toxicity with TKI therapy in CML
  • +1
  • Maria Eduarda Couto,
  • Isabel Oliveira,
  • Sérgio Estrela-Silva,
  • José Mariz
Maria Eduarda Couto
Instituto Português de Oncologia do Porto
Author Profile
Isabel Oliveira
Instituto Portugues de Oncologia do Porto Francisco Gentil EPE
Author Profile
Sérgio Estrela-Silva
Hospital São João
Author Profile
José Mariz
Instituto Portugues de Oncologia do Porto Francisco Gentil EPE
Author Profile

Abstract

Tyrosine kinase inhibitors are the standard treatment for Chronic Myeloid Leukemia. They have significantly improved the response rate and global survival in the long term for CML patients, but also added relevant and diverse toxicity. The authors report a clinical case of ocular toxicity connected to the TKIs.

Peer review status:IN REVISION

31 Mar 2021Submitted to Clinical Case Reports
02 Apr 2021Submission Checks Completed
02 Apr 2021Assigned to Editor
05 Apr 2021Review(s) Completed, Editorial Evaluation Pending
05 Apr 2021Editorial Decision: Revise Minor
13 Apr 20211st Revision Received
16 Apr 2021Submission Checks Completed
16 Apr 2021Assigned to Editor
16 Apr 2021Review(s) Completed, Editorial Evaluation Pending
27 Apr 2021Editorial Decision: Revise Minor